Yield of concurrent systemic biopsy during MRI-targeted biopsy according to Prostate Imaging Reporting and Data System version 2 in patients with suspected prostate cancer.
Chu Hyun KimChan Kyo KimJung Jae ParkSung Yoon ParkYoung Cheol YoonPublished in: European radiology (2020)
• Concurrent SB with MRTB yields an increase of 5.6% CSC detection compared with MRTB alone. • Of both MRTB- and SB-positive findings, 20.0% patients have upgraded Gleason score in SB. • In 18.4% patients, only SB was positive, with negative MRTB. Adding MRTB to SB is helpful for adequate risk stratification, reducing diagnostic uncertainty of PCa.
Keyphrases
- prostate cancer
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- radical prostatectomy
- high resolution
- magnetic resonance
- ultrasound guided
- locally advanced
- mass spectrometry
- patient reported outcomes
- cancer therapy
- big data
- sensitive detection
- fluorescence imaging
- rectal cancer
- psychometric properties
- fine needle aspiration